Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC After Chemotherapy

Slideset - Abemaciclib monotherapy was active in patients with heavily pretreated HR+/HER2- MBC and showed no new safety signals.

Source: Clinical Care Options Breast Cancer - June 6, 2016 Category: Cancer & Oncology Source Type: research